Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001567619-22-017845
Filing Date
2022-09-27
Accepted
2022-09-27 17:00:48
Documents
2
Period of Report
2022-09-23

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 1698
2 kasaharapoa.htm EX-24 8039
  Complete submission text file 0001567619-22-017845.txt   11334
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Issuer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O 4D MOLECULAR THERAPEUTICS, INC. 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address
Kasahara Noriyuki (Reporting) CIK: 0001943840 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39782 | Film No.: 221271882